2024 Recommendations for Validation of Noninvasive Arterial Pulse Wave Velocity Measurement Devices.

aorta cardiovascular diseases guideline pulse wave analysis vascular stiffness

Journal

Hypertension (Dallas, Tex. : 1979)
ISSN: 1524-4563
Titre abrégé: Hypertension
Pays: United States
ID NLM: 7906255

Informations de publication

Date de publication:
17 Nov 2023
Historique:
medline: 17 11 2023
pubmed: 17 11 2023
entrez: 17 11 2023
Statut: aheadofprint

Résumé

Arterial stiffness, as measured by arterial pulse wave velocity (PWV), is an established biomarker for cardiovascular risk and target-organ damage in individuals with hypertension. With the emergence of new devices for assessing PWV, it has become evident that some of these devices yield results that display significant discrepancies compared with previous devices. This discrepancy underscores the importance of comprehensive validation procedures and the need for international recommendations. A stepwise approach utilizing the modified Delphi technique, with the involvement of key scientific societies dedicated to arterial stiffness research worldwide, was adopted to formulate, through a multidisciplinary vision, a shared approach to the validation of noninvasive arterial PWV measurement devices. A set of recommendations has been developed, which aim to provide guidance to clinicians, researchers, and device manufacturers regarding the validation of new PWV measurement devices. The intention behind these recommendations is to ensure that the validation process can be conducted in a rigorous and consistent manner and to promote standardization and harmonization among PWV devices, thereby facilitating their widespread adoption in clinical practice. It is hoped that these recommendations will encourage both users and developers of PWV measurement devices to critically evaluate and validate their technologies, ultimately leading to improved consistency and comparability of results. This, in turn, will enhance the clinical utility of PWV as a valuable tool for assessing arterial stiffness and informing cardiovascular risk stratification and management in individuals with hypertension.

Sections du résumé

BACKGROUND UNASSIGNED
Arterial stiffness, as measured by arterial pulse wave velocity (PWV), is an established biomarker for cardiovascular risk and target-organ damage in individuals with hypertension. With the emergence of new devices for assessing PWV, it has become evident that some of these devices yield results that display significant discrepancies compared with previous devices. This discrepancy underscores the importance of comprehensive validation procedures and the need for international recommendations.
METHODS UNASSIGNED
A stepwise approach utilizing the modified Delphi technique, with the involvement of key scientific societies dedicated to arterial stiffness research worldwide, was adopted to formulate, through a multidisciplinary vision, a shared approach to the validation of noninvasive arterial PWV measurement devices.
RESULTS UNASSIGNED
A set of recommendations has been developed, which aim to provide guidance to clinicians, researchers, and device manufacturers regarding the validation of new PWV measurement devices. The intention behind these recommendations is to ensure that the validation process can be conducted in a rigorous and consistent manner and to promote standardization and harmonization among PWV devices, thereby facilitating their widespread adoption in clinical practice.
CONCLUSIONS UNASSIGNED
It is hoped that these recommendations will encourage both users and developers of PWV measurement devices to critically evaluate and validate their technologies, ultimately leading to improved consistency and comparability of results. This, in turn, will enhance the clinical utility of PWV as a valuable tool for assessing arterial stiffness and informing cardiovascular risk stratification and management in individuals with hypertension.

Identifiants

pubmed: 37975229
doi: 10.1161/HYPERTENSIONAHA.123.21618
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIEHS NIH HHS
ID : P30 ES005605
Pays : United States

Auteurs

Bart Spronck (B)

Department of Biomedical Engineering, CARIM School for Cardiovascular Diseases, Maastricht University, Netherlands (B.S.).
Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW, Australia (B.S., A.P.A., I.T.).

Dimitrios Terentes-Printzios (D)

1st Cardiology Department, Hippokration Hospital, National and Kapodistrian University of Athens, Greece (D.T.-P., C.V.).

Alberto P Avolio (AP)

Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW, Australia (B.S., A.P.A., I.T.).

Pierre Boutouyrie (P)

Université Paris Cité, Inserm, PARCC, France (P.B., S.L., R.M.B.).
Service de Pharmacologie et Hypertension, AP-HP, Hôpital Européen Georges Pompidou, Paris, France (P.B., S.L., R.M.B.).

Andrea Guala (A)

Vall d'Hebron Institut de Recerca, Barcelona, Spain (A.G.).
CIBER-CV, Instituto de Salud Carlos III, Madrid, Spain (A.G.).

Ana Jerončić (A)

Laboratory of Vascular Aging and Cardiovascular Prevention, Department of Research in Biomedicine and Health, University of Split School of Medicine, Croatia (A.J.).

Stéphane Laurent (S)

Université Paris Cité, Inserm, PARCC, France (P.B., S.L., R.M.B.).
Service de Pharmacologie et Hypertension, AP-HP, Hôpital Européen Georges Pompidou, Paris, France (P.B., S.L., R.M.B.).

Eduardo C D Barbosa (ECD)

Feevale University, Santa Casa Hospital, Porto Alegre, Brazil (E.C.D.B).

Johannes Baulmann (J)

Praxis Dres. Gille/Baulmann, Rheinbach, Germany (J.B.).
Division of Cardiology, Medical University of Graz, Austria (J.B.).

Chen-Huan Chen (CH)

Division of Cardiology, Medical University of Graz, Austria (J.B.).

Julio A Chirinos (JA)

Cardiovascular Division, University of Pennsylvania Perelman School of Medicine and Hospital of the University of Pennsylvania, Philadelphia (J.A.C.).

Stella S Daskalopoulou (SS)

Department of Medicine, Research Institute McGill University Health Centre, McGill University, Montreal, QC, Canada (S.S.D.).

Alun D Hughes (AD)

Department of Population Science and Experimental Medicine, Institute of Cardiovascular Science, University College London, United Kingdom (A.D.H.).

Azra Mahmud (A)

Department of Internal Medicine, Pharmacology, and Clinical Research, Shalamar Medical and Dental College, Lahore, Pakistan (A.M.).

Christopher C Mayer (CC)

AIT Austrian Institute of Technology, Center for Health and Bioresources, Medical Signal Analysis, Vienna (C.C.M.).

Jeong Bae Park (JB)

JB Lab and Clinic, Department of Precision Medicine and Biostatistics, Wonju College of Medicine, Yonsei University, Seoul, Republic of Korea (J.B.P.).

Gary L Pierce (GL)

Department of Health and Human Physiology, University of Iowa (G.L.P.).

Aletta E Schutte (AE)

School of Population Health, University of New South Wales, Sydney, Australia (A.E.S.).
The George Institute for Global Health, Sydney, NSW, Australia (A.E.S., I.T.).

Elaine M Urbina (EM)

Cincinnati Children's Hospital Medical Center, OH (E.M.U.).
University of Cincinnati, OH (E.M.U.).

Ian B Wilkinson (IB)

Experimental Medicine and Therapeutics, University of Cambridge, United Kingdom (I.B.W.).

Patrick Segers (P)

IBiTech-BioMMedA, Ghent University, Belgium (P.S.).

James E Sharman (JE)

Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia (J.E.S.).

Isabella Tan (I)

Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW, Australia (B.S., A.P.A., I.T.).
The George Institute for Global Health, Sydney, NSW, Australia (A.E.S., I.T.).

Charalambos Vlachopoulos (C)

1st Cardiology Department, Hippokration Hospital, National and Kapodistrian University of Athens, Greece (D.T.-P., C.V.).

Thomas Weber (T)

Cardiology Department, Klinikum Wels-Grieskirchen, Austria (T.W.).

Elisabetta Bianchini (E)

Institute of Clinical Physiology, Italian National Research Council, Pisa (E.B.).

Rosa Maria Bruno (RM)

Université Paris Cité, Inserm, PARCC, France (P.B., S.L., R.M.B.).
Service de Pharmacologie et Hypertension, AP-HP, Hôpital Européen Georges Pompidou, Paris, France (P.B., S.L., R.M.B.).

Classifications MeSH